For anyone who may be time challenged, here is my overview of an overview from the American Parkinson Disease Association!

Categories covered:
- Alpha-synuclein strategies – decreasing aggregation of alpha-synuclein:
--- Alpha-synuclein antibodies (passive immunity);
--- Alpha-synuclein vaccine (active immunity);
--- Molecules that block alpha-synuclein.
- Glucagon-like peptide-1 (GLP-1) agonist strategies – decreasing neuro-inflammation;
- Glucocerebrosidase (GBA) – enhancing the cell’s lysosomal system;
- LRRK2 strategies;
- c-Abl kinase strategies – decreasing oxidative stress.

The Future of Parkinson’s Disease Treatments | APDA